What is Epitel?
Epitel is a specialized digital health enterprise focused on the development of wearable, wireless EEG monitoring platforms. The company's flagship product, REMI, received FDA clearance in 2021, establishing a new standard for seizure detection within hospital emergency rooms and critical care units. By bridging the gap between complex neurological monitoring and portable, user-friendly hardware, Epitel addresses critical unmet needs in acute care settings. The company operates at the intersection of medical technology and neurology, aiming to improve patient outcomes through continuous, real-time data acquisition and analysis.
How much funding has Epitel raised?
Epitel has raised a total of $38.6M across 3 funding rounds:
Debt
$98K
Series A
$12.5M
Series B
$26M
Debt (2021): $98K with participation from PPP
Series A (2022): $12.5M led by OSF Ventures, Medmountain Ventures, Dexcom, Salt Lake City Angels, Wavemaker Three-Sixty Health, Catalyst Health Ventures, and Genoa Ventures
Series B (2026): $26M supported by Genoa Ventures and Catalyst Health Ventures
Key Investors in Epitel
Genoa Ventures
Genoa Ventures is an investment firm focused on early-stage companies that are innovating at the intersection of biology and technology, aiming to empower category-defining firms.
Catalyst Health Ventures
Catalyst Health Ventures is a venture capital firm dedicated to investing in transformative medical technologies that address global unmet healthcare needs through strategic insight and mentorship.
OSF Ventures
OSF Ventures is a venture capital and private equity firm based in California that focuses on supporting innovative healthcare solutions.
What's next for Epitel?
With this major enterprise-level funding, Epitel is well-positioned to accelerate its market expansion and deepen its clinical footprint. The strategic capital will likely be deployed to scale manufacturing capabilities, enhance the REMI platform's diagnostic algorithms, and broaden its reach into additional clinical environments beyond the emergency room. As the company transitions from its initial commercialization phase into a broader growth stage, the focus will remain on solidifying its technological moat and establishing long-term partnerships with major healthcare systems to standardize its seizure monitoring solutions.
See full Epitel company page
